A multinational, randomized phase iii trial of iseganan hcl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy
详细信息 查看全文
- 作者：Trotti ; Andy ; Garden ; Adam ; Warde ; Padraig ; Symonds ; Paul ; Langer ; Corey ; Redman ; Rebecca ; Pajak ; Thomas F. ; et. al.
- 关键词：Iseganan ; Mucositis ; Oral mucositis ; Radiotherapy ; Head and neck
- 刊名：International Journal of Radiation Oncology*Biology*Physics
- 出版年：2004
- 出版时间：March, 2004
- 年：2004
- 卷：58
- 期：3
- 页码：674-681
- 全文大小：73.7 K
文摘
Oral mucositis (OM) causes significant morbidity during the course of radiotherapy (RT) treatment of head-and-neck cancer. It is hypothesized that infection plays a role in the development of OM. We tested the efficacy of iseganan HCl (iseganan), a synthetic peptide with broad-spectrum antimicrobial activity, for preventing RT-associated OM.